Artelo Biosciences Launches New Public Offering
Artelo Biosciences, Inc. (NASDAQ: ARTL) has taken a significant step in its journey by announcing a proposed underwritten public offering. The company is dedicated to advancing its clinical-stage pharmaceutical initiatives aimed at transforming treatment options for patients confronting cancer, pain, and various neurological and dermatologic conditions.
Details of the Offering
In this offering, Artelo intends to provide its common stock and/or pre-funded warrants, with all shares being offered by the company itself. While the offering is contingent on market conditions, the company remains optimistic about successfully proceeding with this crucial financial endeavor.
Management and Execution
Artelo has appointed R.F. Lafferty & Co., Inc. as the exclusive book-running manager for this public offering. This partnership reflects the company's commitment to maintaining a strong financial platform while attracting investors who share its vision for innovative therapies.
Registration and Prospectus Information
The common stock and pre-funded warrants offered in this public offering are included under a previously filed "shelf" registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC). Originally declared effective on July 14, 2023, this registration statement allows the company to access the capital markets efficiently.
Understanding the Prospectus
The structure of this offering includes a prospectus supplement that will detail the specific terms of the public offering. Interested investors can expect to find comprehensive insights into the offering as this supplement is filed with the SEC soon.
Availability of Documents
Investors wishing to review the offering documents will have access through the SEC's website. The company’s official documents will be made available, ensuring transparency and adherence to regulatory standards.
Contact Information for Requests
Copies of the prospectus supplement and accompanying prospectus can also be requested directly from R. F. Lafferty & Co., Inc., located at 40 Wall Street, Suite 3602, New York, NY 10005. They are available by phone at (212) 293-9090.
About Artelo Biosciences
Artelo Biosciences, Inc. stands at the forefront of pharmaceutical innovation. Its mission revolves around the development of proprietary therapeutics aimed at modulating lipid-signaling pathways. This diverse pipeline includes addressing significant unmet medical needs across disorders such as cancer, anxiety, pain, inflammation, and anorexia.
Commitment to Stakeholders
Backed by a skilled executive team and collaborations with leading researchers, Artelo is dedicated to delivering solid returns for stakeholders. By employing rigorous scientific methods, regulatory compliance, and advanced treasury management practices, the company maximizes its potential impact on patient care and community health.
Investor Relations and Support
The Investor Relations team, reachable through Crescendo Communications, LLC, is readily available to address inquiries. Interested parties can connect by phone at 212-671-1020 or reach out via email at ARTL@crescendo-ir.com.
Frequently Asked Questions
What is Artelo Biosciences known for?
Artelo Biosciences is dedicated to the development of innovative therapeutics targeting various serious medical conditions, including cancer and pain management.
What was the purpose of the public offering?
The public offering aims to bolster the company's financial position and support the ongoing development of its clinical programs.
Who is managing the public offering?
R.F. Lafferty & Co., Inc. is the sole book-running manager for the offering.
Where can I find more information about the offering?
Information can be accessed through the company’s filings with the SEC and will be available on their website.
How can I contact Artelo Biosciences?
Contact can be made through Crescendo Communications at 212-671-1020 or via email at ARTL@crescendo-ir.com.
